Clincosm LogoSign in Get a demo

Expanded Access for ACE-011

Sponsor
Celgene (Industry)
Overall Status
No longer available
CT.gov ID
NCT03724227
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access for ACE-011

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Celgene Summit New Jersey United States 07901

    Sponsors and Collaborators

    • Celgene

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Celgene
    ClinicalTrials.gov Identifier:
    NCT03724227
    Other Study ID Numbers:
    • ACE-011
    First Posted:
    Oct 30, 2018
    Last Update Posted:
    Jul 17, 2020
    Last Verified:
    Oct 1, 2019
    Keywords provided by Celgene
    Expanded Access
    Compassionate Use
    Additional relevant MeSH terms:
    Myelodysplastic Syndromes

    Study Results

    No Results Posted as of Jul 17, 2020